Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 9/20 | 0.59 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | RAD52 | P43351 | 3/20 | 0.50 |
| ▸ | TOP2A | P11388 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559637 | 0.84 | SLC2A1 (0.72) | SLC2A1CACNA2D1ELANEPOLBRAD52 | |
| SCHEMBL9415866 | 0.83 | SLC2A1 (0.75) | SLC2A1CACNA2D1ELANEPOLBRAD52 | |
| Hydrochloric Acid SCHEMBL8651166 | 0.82 | SLC2A1 (0.78) | SLC2A1CACNA2D1ELANEPOLBRAD52 | |
| SCHEMBL9748474 | 0.80 | POLB (0.70) | SLC2A1CACNA2D1ELANEPOLBRAD52 | |
| SCHEMBL5578493 | 0.76 | POLB (0.79) | SLC2A1CACNA2D1POLBRAD52RAB9A | |
| SCHEMBL6033155 | 0.75 | POLB (0.77) | SLC2A1CACNA2D1POLBRAD52RAB9A | |
| SCHEMBL13856923 | 0.75 | POLB (0.77) | SLC2A1CACNA2D1POLBRAD52RAB9A | |
| SCHEMBL28158394 | 0.73 | POLB (0.68) | SLC2A1CACNA2D1POLBRAD52TOP2A | |
| SCHEMBL7869214 | 0.73 | POLB (0.79) | SLC2A1CACNA2D1POLBRAD52TOP2A | |
| SCHEMBL5478992 | 0.73 | KDM1A (0.66) | POLBRAD52TOP2AKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006041900-A9 | SUBSTITUTED N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20070253957-A1 | Substituted N-Aryl-1H-Pyrazolo[3,4-B]Quinolin-4-Amines and Analogs as Activators of Caspases and Inducers of Apoptosis | CYTOVIA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070253957-A1 | Substituted N-Aryl-1H-Pyrazolo[3,4-B]Quinolin-4-Amines and Analogs as Activators of Caspases and Inducers of Apoptosis | CYTOVIA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070253957-A1 | Substituted N-Aryl-1H-Pyrazolo[3,4-B]Quinolin-4-Amines and Analogs as Activators of Caspases and Inducers of Apoptosis | CYTOVIA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| EP-1807426-A2 | SUBSTITUTED N-ARYL-1H-PYRAZOLOÝ3,4-b¨QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006041900-A3 | SUBSTITUTED N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006041900-A2 | SUBSTITUTED N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070253957-A1 | Substituted N-Aryl-1H-Pyrazolo[3,4-B]Quinolin-4-Amines and Analogs as Activators of Caspases and Inducers of Apoptosis | CASP3, CASP7, CASP4 | SLC2A1 4439/4885CACNA2D1 2933/4885ELANE 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.